MaSTherCell, (Manufacturing Synergies for Therapeutic Cells) was founded in 2011 as a cell therapy dedicated Contract Development and Manufacturing Organization (CDMO). From the outset, the aim of the company was to combine academic and industry excellence to provide unparalleled quality manufacturing services.
The company was set up with investment from the founders as well as from institutional investors Sambrinvest and Sofipole and other private investors, and also with the support of the Walloon Region and its Life Sciences cluster, BioWin.
Located in just 40 minutes from Brussels, the capital of Europe, MaSTherCell's state-of-the-art facilities in theI-tech Incubator Building in Gosselies are now fully operational and received the final cGMP manufacturing authorization from the BelgianDrug Agency (AFMPS) in September 2013.
MaSTherCell's considerable expertise is based on the background of its principals who, between them, combine close to 100 years of senior managerial and scientific experience in the Life Sciences sector.
Through a reversible deal, MaSTherCell has been acquired by Orgenesis (a leader in the emerging fields of cellular therapy and re-generative medicine for the treatment of Type 1 Diabetes) in March 2015. MaSTherCell will be responsible for the development and the commercialization of Orgenesis' product and will also maintain his CDMO core business activity in an independent way.
In 2017, MaSTherCell will reach more than 100 employees with a global presence in order to crystalize its position as ultimate cell therapy manufacturing partner for leading biotech companies targeting a fast and cost effective development of their product to the market.